KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) FCF Margin (2018 - 2025)

Castle Biosciences (CSTL) has disclosed FCF Margin for 8 consecutive years, with 23.03% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 702.0% to 23.03% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 15.4% through Dec 2025, down 413.0% year-over-year, with the annual reading at 15.4% for FY2025, 413.0% down from the prior year.
  • FCF Margin hit 23.03% in Q4 2025 for Castle Biosciences, down from 30.11% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 42.14% in Q3 2024 to a low of 81.3% in Q1 2022.
  • Historically, FCF Margin has averaged 8.41% across 5 years, with a median of 13.94% in 2022.
  • Biggest five-year swings in FCF Margin: tumbled -13179bps in 2021 and later soared 4655bps in 2024.
  • Year by year, FCF Margin stood at 24.26% in 2021, then dropped by -13bps to 27.39% in 2022, then soared by 132bps to 8.87% in 2023, then surged by 239bps to 30.05% in 2024, then decreased by -23bps to 23.03% in 2025.
  • Business Quant data shows FCF Margin for CSTL at 23.03% in Q4 2025, 30.11% in Q3 2025, and 21.74% in Q2 2025.